Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: J Thorac Oncol. 2017 Feb 4;12(5):833–842. doi: 10.1016/j.jtho.2017.01.023

Figure 1. Examples of best responses on HER2 directed therapies.

Figure 1

A. Patient #1 at beginning of therapy (Left) and 5 months after starting vinorelbine and trastuzumab (Right)

B. Patient #2 at beginning of therapy (Left) and 3.5 months after starting vinorelbine and trastuzumab (Right)

C. Patient #3 at beginning of therapy (Left) and 2 months after starting vinorelbine and trastuzumab (Right)

D. Patient #4 at beginning of therapy (Left) and 2 months after starting afatinib (Right)

E. Patient #4 at beginning of therapy (Left) and 3.5 months after starting vinorelbine and trastuzumab (Right)

F. Patient #4 at beginning of therapy (Left) and 1 month after starting afatinib and bevacizumab (Right)